SCHEMBL30748969

SCHEMBL30748969

CC1(C)CN(c2ccc(Oc3ccccc3)cc2)c2nc(C=O)ncc21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLCG1 P19174 1/20 0.35
TSHR P16473 2/20 0.33
HPGD P15428 1/20 0.33
KAT2B Q92831 1/20 0.33
MGLL Q99685 3/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
IDH1 O75874 1/20 0.32
MCHR2 Q969V1 1/20 0.32
MCHR1 Q99705 1/20 0.32
HRH4 Q9H3N8 1/20 0.32
LMNA P02545 1/20 0.32
TEC P42680 1/20 0.32
BTK Q06187 1/20 0.32
EGLN1 Q9GZT9 1/20 0.32
P2RY1 P47900 1/20 0.32
TNK2 Q07912 1/20 0.32
MEN1 O00255 1/20 0.31
USP2 O75604 1/20 0.31
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30749008 0.89 PLCG1 (0.33) PLCG1KAT2BMGLLSMN1; SMN2MCHR2
SCHEMBL30749020 0.83 PIN1 (0.40) PLCG1KAT2BMGLLRAB9ASMN1; SMN2
SCHEMBL30748853 0.81 POLB (0.36) PLCG1SMN1; SMN2MCHR2MCHR1HRH4
SCHEMBL30749037 0.78 APP (0.37) PLCG1
SCHEMBL30749085 0.75 EGLN1 (0.44) PLCG1MGLLBTKEGLN1USP2
SCHEMBL31691289 0.73 KDM4E (0.41) HPGDSMN1; SMN2IDH1ALDH1A1
SCHEMBL31691357 0.72 MCHR2 (0.33) MCHR2MCHR1HRH4TECBTK
SCHEMBL30748892 0.70 MGLL (0.41) PLCG1HPGDKAT2BMGLLSMN1; SMN2
SCHEMBL30749030 0.69 PIN1 (0.40) PLCG1MGLLRAB9AMCHR2MCHR1
SCHEMBL30749049 0.69 PSEN1 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT PLCG1 4086/4885TSHR 4739/4885HPGD 426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.